ADMA Biologics, Inc. (NASDAQ:ADMA) Given Consensus Rating of “Buy” by Brokerages

ADMA Biologics, Inc. (NASDAQ:ADMA) has earned an average recommendation of “Buy” from the four research firms that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $7.88.

Several analysts have issued reports on ADMA shares. HC Wainwright restated a “buy” rating and issued a $7.50 target price (up from $6.00) on shares of ADMA Biologics in a research note on Tuesday, March 26th. Mizuho boosted their target price on ADMA Biologics from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Cantor Fitzgerald boosted their target price on ADMA Biologics from $6.50 to $8.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th.

Insider Activity

In other news, Director Steve Elms sold 407,000 shares of ADMA Biologics stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $6.21, for a total value of $2,527,470.00. Following the completion of the transaction, the director now directly owns 3,208,671 shares in the company, valued at $19,925,846.91. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last three months, insiders sold 639,895 shares of company stock worth $3,927,169. 5.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ADMA Biologics

Several hedge funds have recently made changes to their positions in ADMA. Vanguard Group Inc. grew its position in ADMA Biologics by 2.7% during the third quarter. Vanguard Group Inc. now owns 12,781,695 shares of the biotechnology company’s stock worth $45,758,000 after buying an additional 336,190 shares in the last quarter. Stonepine Capital Management LLC grew its position in ADMA Biologics by 1.3% during the fourth quarter. Stonepine Capital Management LLC now owns 9,222,617 shares of the biotechnology company’s stock worth $41,686,000 after buying an additional 118,342 shares in the last quarter. Invesco Ltd. grew its position in ADMA Biologics by 8.5% during the third quarter. Invesco Ltd. now owns 5,417,166 shares of the biotechnology company’s stock worth $19,393,000 after buying an additional 426,446 shares in the last quarter. American Century Companies Inc. grew its position in ADMA Biologics by 20.8% during the third quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company’s stock worth $17,514,000 after buying an additional 840,761 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its position in ADMA Biologics by 15.1% during the third quarter. Adage Capital Partners GP L.L.C. now owns 3,767,558 shares of the biotechnology company’s stock worth $13,488,000 after buying an additional 493,000 shares in the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Stock Down 0.9 %

ADMA stock opened at $6.52 on Wednesday. ADMA Biologics has a twelve month low of $3.06 and a twelve month high of $6.76. The company has a quick ratio of 1.69, a current ratio of 5.16 and a debt-to-equity ratio of 1.04. The stock’s 50 day moving average is $6.12 and its 200-day moving average is $4.94. The firm has a market capitalization of $1.49 billion, a PE ratio of -50.15 and a beta of 0.46.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. The business had revenue of $73.90 million for the quarter, compared to analyst estimates of $73.50 million. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. Sell-side analysts expect that ADMA Biologics will post 0.3 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.